Key result
Aspirin yields similar non-adherence to enoxaparin for VTE prophylaxis after hip or knee arthroplasty.
Why the study?
Aspirin and enoxaparin are commonly used for VTE prophylaxis after THA or TKA, but comparative data on patient-reported non-adherence after discharge are limited.
Does aspirin improve patient-reported adherence compared to enoxaparin for VTE prophylaxis after hip or knee arthroplasty?
RCT (n=178)
Yes
Does aspirin improve patient-reported adherence compared to enoxaparin for VTE prophylaxis after hip or knee arthroplasty?
Odds Ratio: 1.4 (95% CI 0.7–2.9)
Absolute Event Rate: 24% vs 30%
Patient-reported non-adherence to VTE prophylaxis after hip or knee arthroplasty is similar between aspirin and enoxaparin.
Similar non-adherence observed does not support aspirin preference; leaves open randomized confirmation of adherence differences post-arthroplasty.
BACKGROUND: Aspirin and enoxaparin are commonly used for venous thromboembolism (VTE) prophylaxis following total hip arthroplasty (THA) or total knee arthroplasty (TKA). The purpose of this study was to compare non-adherence after discharge to aspirin or enoxaparin following THA or TKA. METHODS: A subset of participants in the CRISTAL study were selected for participation. Additional inclusion criteria were no preoperative anticoagulant use and discharge from hospital before the prophylaxis period ended. The first four consecutive patients from each arm at each participating hospital were planned to be recruited (planned sample size n = 248). A patient-reported adherence questionnaire was completed by telephone at 36-41 days after THA and at 15-20 days after TKA. The primary outcome was non-adherence. Secondary outcomes were number of missed doses and the reasons for non-adherence. RESULTS: There were 178 participants included from 15 sites, less than planned explained by early stopping of trial recruitment. There was no significant between-group difference in patient-reported non-adherence: 24% (17/71) for aspirin, 30% (32/107) for enoxaparin, odds ratio = 1.4 (95% CI 0.7-2.9). The mean number of missed doses was 2.5 for aspirin and 3.4 for enoxaparin (mean difference = 0.9 doses, 95% CI -1.2 to 3.1). For aspirin, the most commonly reported reason for non-adherence was forgotten doses and for enoxaparin it was clinician-recommended change. CONCLUSIONS: Rates of non-adherence and the number of missing doses were similar for patients regardless of drug prescribed. The most common reasons for non-adherence were unrelated to the mode of administration.
No takes yet. Share an insight, caveat, or question.
Sidhu et al. (2023) conducted an RCT in Venous thromboembolism (VTE) prophylaxis following total hip or knee arthroplasty (n=178). Aspirin vs. Enoxaparin was evaluated on Patient-reported non-adherence (OR 1.4, 95% CI 0.7-2.9). Patient-reported non-adherence to aspirin was similar to enoxaparin for VTE prophylaxis after hip or knee arthroplasty (24% vs 30%; OR 1.4, 95% CI 0.7-2.9).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: